Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

altRX vs RestorLife Med

altRX
Graded #92

Higher grade

vs+6.1000000000000085
RestorLife Med
Graded #222

Lower grade

The verdict

altRX takes it — 71.4/100 to 65.3/100.

altRX grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. altRX is a dual-modality telehealth platform offering compounded GLP-1s plus all four brand-name FDA-approved options — Mounjaro, Ozempic, Wegovy, and Zepbound — the most comprehensive brand-name lineup in…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valuealtRX +30
74
44
Dose & formulationaltRX +25
77
52
Clinical oversightRestorLife Med +15
82
97
Labs & monitoringRestorLife Med +13
53
66
FulfillmentRestorLife Med +24
73
97
Contract termsaltRX +18
55
37
altRX · left barRestorLife Med · right bar

The numbers

MetricaltRXRestorLife Med
WeighScore71.4/10065.3/100
GradeCC
Scorecard rank#92#222
Semaglutide$149/mo (starting dose, compounded)$199/mo (6-month plan, compounded)
Tirzepatide$249/mo (starting dose, compounded)Not disclosed
CoverageCoverage not publishedAll 50 states
Brand-name accessYesCompounded only
Oral / sublingualInjection onlyInjection only
altRX

Graded #92 · C

Strengths

  • Offers all four brand-name FDA-approved GLP-1s (Mounjaro, Ozempic, Wegovy, Zepbound) — the most comprehensive brand-name access we've reviewed
  • LegitScript Certified with a publicly verifiable seal
  • Publishes the FDA compounded-medication disclaimer
  • Transparent pricing across all six product tiers (compounded plus four brand-name)
  • All-inclusive pricing — consult, prescription, and shipping with no hidden fees

Where it loses points

  • States-served list not disclosed
  • 503A/503B pharmacy partner not named (only 'multiple USA-certified pharmacies')
  • 503A vs 503B designation not specified
  • No named medical director
  • Corporate physical address not disclosed
RestorLife Med

Graded #222 · C

Strengths

  • Verifiable LegitScript certification (seal ID 50400451) plus a named board-certified physician (Dr. Michael Wasef, MD) licensed in all 50 states
  • Full GLP-1 lineup: compounded semaglutide and tirzepatide, plus gentler microdose entry options
  • Generous support — unlimited care-team messaging, monthly check-ins, dosage adjustments, and 1 free blood test per quarter on the GLP-1 protocols
  • Available in all 50 states with free priority shipping, discreet packaging, and roughly 48-hour delivery
  • Transparent multi-month pricing with 50% off your first month; semaglutide protocols are compounded with B12

Where it loses points

  • The advertised $299 is a struck-through anchor price, not a starting point: the real month-to-month rate is $299, a first month runs $149 at 50% off, and the $199 rate needs six months
  • The page states its pricing is 'introductory and subject to change', so none of these figures is committed to
  • The tirzepatide price is published the same way, against a struck-through anchor, and we could not establish which figure a buyer actually pays
  • A separate semaglutide microdose is sold at $99/mo — a sub-therapeutic protocol, not a cheaper weight-loss dose
  • Compounded semaglutide and tirzepatide are not FDA-approved finished products

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard